Curaleaf Q2 2026 revenue rises 10% as wholesale growth offsets price pressure, company says
Gross profit and margin improve
Gross profit climbed to US$169.9 million; margin improved to 50% as mix shifted, despite higher cost of goods sold tied to faster wholesale growth.
Operating expenses weigh on operating income
Operating expenses rose 13% to US$165.7 million on higher compensation, lobbying and public relations, branding and marketing, pushing operating income down to US$4.2 million.
Q2 revenue rises on retail expansion and wholesale growth
Curaleaf posted Q2 revenue of US$340.1 million, up 10%, driven by retail footprint expansion, international patient growth, and new wholesale partnerships.
Retail revenue rose 5% to US$240.7 million, led by new store openings; pricing pressure and tougher competition offset gains.
Wholesale revenue increased 21% to US$96 million, supported by expanded partner distribution; international results benefited from the QMID device launch.
